Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
Eker rats have a germline mutation in tuberous sclerosis 2 gene (Tsc2). Heterozygous mutants develop renal cell carcinomas (RCCs) within one year after birth, whereas homozygous mutants are embryonic lethal. To explore new strategies for treatment of cancer using epigenetic modification, we started studies with reprogramming of Eker rat’s cancer cells as a model case. For that, we first tried to generate Tsc2-deficient ES cells (ESCs) and embryonic fibroblast-derived iPS cells (iPSCs) from Eker rat’s, and analyzed effects of Tsc2-deficiency on pluripotency. We are characterizing them in terms of stemness and pluripotency.
|